R&D News | pharmaphorum

News

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

News

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.

News

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Readout for AZ's hypoparathyroidism drug raises questions

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

News

Novo, Lilly trade oral GLP-1 data readouts at ECO

Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.

News

Isomorphic raises $1.2bn for AI drug hunt

Isomorphic Labs has added to the lustre attached to its AI-powered drug discovery engine by raising an eye-watering $1.2 billion in a Series B round.

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

AZ cues up broader use of Imfinzi in bladder cancer

Readout for AZ's hypoparathyroidism drug raises questions

Novo, Lilly trade oral GLP-1 data readouts at ECO

Isomorphic raises $1.2bn for AI drug hunt

Trustworthy and novel AI in clinical trial planning, with Kr...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks